Clinical Trials Logo

Clinical Trial Summary

This is a single-center, open-label, crossover trial with two arms and two periods (2x2) and one-week washout period. The study is designed to evaluate the efficacy of an AI-based bedtime smart snack intervention in reducing nocturnal low glucose in people living with T1D on MDI therapy compared with traditional CGM-augmented MDI therapy as the control.


Clinical Trial Description

Participants will be randomized to either first use CGM only to manage glucose for four weeks (control arm) followed by four weeks of DailyDose App + bedtime smart snack intervention (intervention arm), or vice-versa. There will be a one-week washout period between arms. During the control arm, participants will wear CGM and will manage their glucose as usual. Participants will be asked to wear a smart watch overnight to collect sleep metrics, weigh themselves weekly in the morning before eating, and answer a one-item sleep quality scale survey weekly. We will collect CGM measurements during the control arm for evaluation of effect of intervention and assessment of the accuracy of low glucose prediction. During the intervention arm, participants will use the DailyDose Smart Snack smart phone app. When they are getting ready for bed, an AI-based model in DailyDose will predict the likelihood of overnight low glucose at bedtime and will recommend a personalized snack to help avoid nocturnal hypoglycemia. The nutritional content of the snack (carbohydrate, protein, fat, etc.) will be dependent on the predicted overnight minimum glucose and the predicted time of the minimum overnight glucose level. During this arm, participants will also be asked to wear a smart watch overnight, weigh themselves weekly, and answer a one-item sleep quality scale survey weekly. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05967260
Study type Interventional
Source Oregon Health and Science University
Contact Clara Mosquera-Lopez, PhD
Phone 503-418-9331
Email mosquera@ohsu.edu
Status Recruiting
Phase N/A
Start date September 1, 2023
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT04712266 - A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes Early Phase 1
Completed NCT06097689 - A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults With Type-1 Diabetes Mellitus N/A
Completed NCT03286816 - The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia N/A
Recruiting NCT05221359 - Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes N/A
Recruiting NCT06382350 - Glycemic Excursions in Patients With Type 1 Diabetes Mellitus Using Closed-loop Systems
Recruiting NCT04266379 - Efficacy of Closed-loop Insulin Therapy in Adults Prone to Hypoglycemia N/A
Completed NCT03163511 - A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness Phase 1/Phase 2
Recruiting NCT05762107 - A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes Phase 2
Active, not recruiting NCT04614168 - Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes N/A
Completed NCT03028220 - Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data N/A
Enrolling by invitation NCT04233138 - SUPPORT Online Training Platform for Type 1 Diabetes Self-management Education and Support (SUPPORT) N/A
Recruiting NCT04664764 - Intermediate and Long Acting Insulin Young Children Type 1 Diabetes. Phase 4